A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma

American Journal of Surgical Pathology

Volumn 39, Issue 5, 2015, Pages 652-659

  Chou, Angela ^a,d,e   Fraser, Sheila ^b   Toon, Christopher W ^a,f   Clarkson, Adele ^a,c   Sioson, Loretta ^a,c   Farzin, Mahtab ^a,c   Cussigh, Carmen ^a   Aniss, Ahmad ^b,c   O'Neill, Christine ^b   Watson, Nicole ^a   Clifton Bligh, Roderick J ^a,c   Learoyd, Diana L ^a,c   Robinson, Bruce G ^a,c   Selinger, Christina I ^g   Delbridge, Leigh W ^b   Sidhu, Stanley B ^b   O'Toole, Sandra A ^b,e,g   Sywak, Mark ^b   Gill, Anthony J ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f Histopath Pathology   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

ALK; EML4 ALK; papillary thyroid carcinoma; thyroid cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ALGORITHM; CARCINOMA; CHILD; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TISSUE MICROARRAY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84928582735     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000368     Document Type: Article

References (35)

1. Davies L, Welch G. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
2. Gonzalez-Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG, et al. Papillary Thyroid Carcinoma: Differential Diagnosis and Prognostic Values of Its Different Variants: Review of the Literature. ISRN Oncology 2011;2011:915925.doi:10.5402/2011/915925.
3. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004:51-80.
4. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002; 26:879-885.
5. Nixon I, Ganly I, Patel SG, et al. Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg. 2012;10:618-623.
6. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184-199.
7. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256-1264.
8. Gandhi M, Evdokimova V, Nikiforov YE. Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321:36-43.
9. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321: 44-49.
10. Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAFv600e detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012;19:779-784.
11. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
12. Kelly LM, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci USA. 2014; 111:4233-4238.
13. Mcfadden DG, Dias-Santagata D, Sado PM, et al. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014; 99:E2457-2462.
14. Pérot G, Soubeyran I, Ribeiro A, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One. 2014;9:e87170.
15. Demeure MJ, Aziz M, Rosenberg R, et al. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014;38:1296-1305.
16. The Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell. 2014;159: 676-690.
17. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011;9(suppl 5):S1-32.
18. Godbert Y, Henriques de Figueiredo B, Bonichon F, et al. Remarkable response to crizotinib in 71-year old woman with ALk-rearranged anaplastic thyroid carcinoma. J Clin Oncol. 2014. [Epub ahead of print].
19. Houang M, Toon CW, Clarkson A, et al. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology. 2014;46:383-388.
20. O'Neill CJ, Bullock M, Chou A, et al. BRAF(v600e) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148:1139-1145.
21. Kruijff S, Aniss AM, Chen P, et al. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma. Surgery. 2013;154: 1337-1344.
22. Schlumberger M, Sherman S. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol. 2012;166:5-11.
23. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511.
24. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148-156.
25. Durante C, Haddy N, Baudin E, et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
26. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
27. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693-1703.
28. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51.
29. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545-1553.
30. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7: 348-354.
31. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6: 459-465.
32. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Society of for the Study of Lung Cancer/Association of Molecular Pathologists Guideline. J Clin Oncol. 2014;32:3673-3679.
33. Hamatani K, Mukai M, Takahashi K, et al. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. Thyroid. 2012;22: 1153-1159.
34. Sheu S-Y, Schwertheim S, Worm K, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol. 2007;20: 779-787.
35. Jankovic B I, Le KT, Hershman JM. Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab. 2013;98:474-482.